Home › Chronic Myeloid Leukemia › Utah › Salt Lake City
Chronic Myeloid Leukemia clinical trials in Salt Lake City, UT
3 studies for Chronic Myeloid Leukemia are looking for participants at sites in and around Salt Lake City (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
RecruitingPhase 2
- Huntsman Cancer Institute, Salt Lake City
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- University of Utah, Salt Lake City
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL)
RecruitingPhase 1/2
- Huntsman Cancer Institute, Salt Lake City
About Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It usually affects older adults. Learn about symptoms, genetics, and treatment.
More about Chronic Myeloid Leukemia on MedlinePlus
Chronic Myeloid Leukemia trials in other cities
- Houston, TX18 studies
- Seattle, WA11 studies
- New York City, NY11 studies
- Philadelphia, PA6 studies
- Birmingham, AL6 studies
- Portland, OR6 studies
- Detroit, MI6 studies
- Baldwin Park, CA6 studies
- Chicago, IL6 studies
- Durham, NC5 studies
- Nashville, TN5 studies
- Boston, MA5 studies
Other studies in Salt Lake City
- Non-Small Cell Lung Cancer31 studies
- Cancer (all types)27 studies
- Breast Cancer27 studies
- Colorectal Cancer22 studies
- Lung Cancer21 studies
- Melanoma21 studies
- Multiple Myeloma21 studies
- Metastatic Cancer20 studies
- Ovarian Cancer19 studies
- Obesity18 studies
- Acute Myeloid Leukemia17 studies
- Heart Failure17 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.